De-escalation of Commonly Used Bone-Treating Agents Is A Reasonable Treatment Option for Patients with Bone Metastases from Breast Cancer
The frequency of administration of bone-treating agents did not affect Quality of Life outcomes
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Molecular Analysis of Samples from the AURORA Programme Is Underway
Integrated molecular analyses shed light on alterations correlated with disease progression and therapeutic resistance in metastatic breast cancer
EMA Recommends Granting a Conditional Marketing Authorisation for Cemiplimab
It is indicated for the treatment of advanced cutaneous squamous cell carcinoma
The results of the ANNOUNCE study show that olaratumab with doxorubicin does not prolong the lives of patients with soft tissue sarcoma
The results of the ANNOUNCE study show that olaratumab with doxorubicin does not prolong the lives of patients with soft tissue sarcoma
EMA Recommends Granting a Marketing Authorisation for Talazoparib
It received a positive opinion for the treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative locally advanced or metastatic breast cancer
Ovarian Cancer Organoids
A biobank of ovarian cancer organoids provide resource for research and precision medicine
A Spotlight on Precision Cancer Medicine
Results fromtheTARGET, I-PREDICT and WINTHER studies released
FDA Approves Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma
Approval is based on results from the KEYNOTE‑426 study
EMA Starts New Review of Risks with High-strength Estradiol-containing Creams
Systemic absorption is of concern because it may result in side effects such as venous thromboembolism, stroke and endometrial cancer
FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma
Approval of FGFR inhibitor is based on data from a cohort of patients enrolled on Study BLC2001
FDA Expands Pembrolizumab Indication for First-line Treatment of NSCLC (TPS ≥1%)
Approval is based on the results from KEYNOTE‑042 study
First-line Durvalumab Improves Survival Compared to Chemotherapy in Metastatic NSCLC
Two analyses from the MYSTIC study show improved survival supporting the use of front-line durvalumab over chemotherapy in metastatic NSCLC